(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 July 2007 (26.07.2007)

PCT

(10) International Publication Number
WO 2007/084786 A1

(51) International Patent Classification:
C07D 401/04 (2006.01) *C07D 417/12* (2006.01)
C07D 401/14 (2006.01) *A61K 31/506* (2006.01)
C07D 405/12 (2006.01) *A61P 35/00* (2006.01)
C07D 405/14 (2006.01)

(21) International Application Number:
PCT/US2007/001708

(22) International Filing Date: 22 January 2007 (22.01.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/760,789 20 January 2006 (20.01.2006) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors: **PICK, Teresa**; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **BARSANTI, Paul**; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **IWANOWICZ, Edwin**; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **FANTL, Wendy**; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **HENDRYCKSON, Tom**; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **KNAPP, Mark**; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **MERITT, Hanne**; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **VOLIVA, Charles**; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **WIESMANN, Marion**; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **XIN, Xiahua**; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US).


(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BURGER, Matthew** [US/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., P.O. Box 8097, Emeryville, CA 94662-8097 (US). **NI, Zhi-jie** [UG/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., P.O. Box 8097, Emeryville, CA 94662-8097 (US). **PECCHI, Sabina** [—/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., P.O. Box 8097, Emeryville, CA 94662-8097 (US). **ATALLAH, Gordana** [—/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., P.O. Box 8097, Emeryville, CA 94662-8097 (US). **BARTULLIS, Sarah** [—/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., P.O. Box 8097, Emeryville, CA 94662-8097 (US). **FRAZIER, Kelly** [US/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., P.O. Box 8097, Emeryville, CA 94662-8097 (US). **SMITH, Aaron** [US/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **VERHAGEN, Joelle** [—/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **ZHANG, Yanchen** [—/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **WAGMAN, Allan** [US/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **NG, Simon** [US/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **PFISTER, Keith** [US/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **POON, Daniel** [US/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US). **LOUIE, Alicia** [—/US]; C/O NOVARTIS VACCINES AND DIAGNOSTICS INC., PO Box 8097, Emeryville, CA 94662-8097 (US).

(74) Agents: **SUH, Young, J.** et al.; NOVARTIS VACCINES AND DIAGNOSTICS INC., CORPORATE INTELLECTUAL PROPERTY R338, P.O. Box 897, Emeryville, CA 94662-8097 (US).

[Continued on next page]

(54) Title: PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS



(I)

(57) Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof ; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

WO 2007/084786 A1

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.